- Tools for Investors
- Stock News
- Investing Ideas
- Econ & Policy
- Personal Finance
Acadia Pharmaceuticals (NASDAQ:ACAD): Roth Capital is convinced that a Phase III trial of ACADIA’s pimavanserin for psychosis in Parkinson’s disease showed strong efficacy results supporting the $1 billion potential for the drug. The firm keeps its Buy rating and an $11 price target on the stock.
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
There's always a bull market in some sector! Find the best opportunities in commodities.